The Russian Direct Investment Fund (RDIF) has made an investment in Geropharm, a Russian pharmaceutical company, specialising in restoring brain function and the treatment of diabetes.
This investment utilises the mechanism designed to promote the development of companies with significant export potential.
The proceeds will be used by Geropharm for the construction of a high-tech full-cycle production complex in St. Petersburg as well as to the development of new drugs and exports. The new facility will enable the company to significantly increase production volumes.
Geropharm is included in the list of the most promising domestic pharmaceutical companies. In addition to production, the company undertakes independent fundamental research to develop new life enhancing products.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), says: "Geropharm has a number of competitive advantages against European manufacturers, including significantly lower productions costs. After the construction of new production facilities, the company will successfully compete with global producers in Russia and abroad. In particular, Geropharm has considerable potential to increase exports to Latin America, Asia-Pacific, Middle East and Europe. The transaction is in line with RDIF’s strategy of investing in the health sector."